Literature DB >> 26209270

Acute and sub-chronic toxicity study of diaveridine in Wistar rats.

Xu Wang1, Shijia Su1, Awais Ihsan2, Qin Huang3, Dongmei Chen3, Guyue Cheng3, Zhenli Liu4, Yulian Wang5, Zonghui Yuan6.   

Abstract

Diaveridine, a developed dihydrofolate reductase inhibitor, has been widely used as anticoccidial drug and antibacterial synergist. However, few studies have been performed to investigate its toxicity. To provide detailed toxicity with a wide spectrum of doses for diaveridine, acute and sub-chronic toxicity studies were conducted. Calculated LD50 was 2330 mg/kg b.w. in females and 3100 mg/kg b.w. in males, and chromodacryorrhea was noted in some females before their death. In the sub-chronic study, diaveridine was fed to Wistar rats during 90 days at dietary levels of 0, 23, 230, 1150 and 2000 mg/kg, which were about 0, 2.0-2.3, 21.0-23.5, 115.2-126.9 and 212.4-217.9 mg/kg b.w., respectively. Significant decrease in body weights in both genders at 1150 and 2000 mg/kg groups and significant increases in relative weights of brain in both genders, liver in females, kidneys and testis in males, alkaline phosphatase and potassium in both genders at 2000 mg/kg diet were noted. Significant decrease in absolute weights of several organs, hemoglobin and red blood cell count in both genders, albumin and total protein in females were observed at 2000 mg/kg diet. Fibroblasts in the kidneys, cell swelling of the glomerular zone in the adrenals and inflammation in the liver were found at 2000 mg/kg group. The no-observed-adverse-effect level of diaveridine was 230 mg/kg diet (21.0-23.5 mg/kg b.w./day).
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acute study; Diaminopyrimidines; Diaveridine; Sub-chronic study; Toxicity

Mesh:

Substances:

Year:  2015        PMID: 26209270     DOI: 10.1016/j.yrtph.2015.07.010

Source DB:  PubMed          Journal:  Regul Toxicol Pharmacol        ISSN: 0273-2300            Impact factor:   3.271


  1 in total

1.  Acute and subacute toxicity profiles of thymoquinone-loaded nanostructured lipid carrier in BALB/c mice.

Authors:  Yong Sze Ong; Latifah Saiful Yazan; Wei Keat Ng; Mustapha M Noordin; Sarah Sapuan; Jhi Biau Foo; Yin Sim Tor
Journal:  Int J Nanomedicine       Date:  2016-11-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.